These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1799 related articles for article (PubMed ID: 25127679)

  • 1. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: a population-based study in Utah.
    Samadder NJ; Curtin K; Tuohy TM; Rowe KG; Mineau GP; Smith KR; Pimentel R; Wong J; Boucher K; Burt RW
    Gastroenterology; 2014 Oct; 147(4):814-821.e5; quiz e15-6. PubMed ID: 25042087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.
    Wong MC; Ching JY; Chan VC; Lam TY; Shum JP; Luk AK; Wong SS; Ng SC; Ng SS; Wu JC; Chan FK; Sung JJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1472-9. PubMed ID: 25724708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-degree relatives of colorectal cancer patients are likely to show advanced colorectal neoplasia despite a negative fecal immunochemical test.
    Cha JM; Lee JI; Joo KR; Shin HP; Park JJ; Jeun JW; Lim JU
    Digestion; 2012; 86(4):283-7. PubMed ID: 23051697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal immunochemical test accuracy in familial risk colorectal cancer screening.
    Castro I; Cubiella J; Rivera C; González-Mao C; Vega P; Soto S; Hernandez V; Iglesias F; Teresa Alves M; Bujanda L; Fernández-Seara J
    Int J Cancer; 2014 Jan; 134(2):367-75. PubMed ID: 23818169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study.
    Samadder NJ; Curtin K; Tuohy TM; Pappas L; Boucher K; Provenzale D; Rowe KG; Mineau GP; Smith K; Pimentel R; Kirchhoff AC; Burt RW
    Gastroenterology; 2014 Apr; 146(4):950-60. PubMed ID: 24417818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
    Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
    Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a colonoscopic screening programme in first-degree relatives of patients with colorectal cancer.
    Puente Gutiérrez JJ; Marín Moreno MA; Domínguez Jiménez JL; Bernal Blanco E; Díaz Iglesias JM
    Colorectal Dis; 2011 Jun; 13(6):e145-53. PubMed ID: 21564467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah.
    Tuohy TM; Rowe KG; Mineau GP; Pimentel R; Burt RW; Samadder NJ
    Cancer; 2014 Jan; 120(1):35-42. PubMed ID: 24150925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
    Chiu HM; Ching JY; Wu KC; Rerknimitr R; Li J; Wu DC; Goh KL; Matsuda T; Kim HS; Leong R; Yeoh KG; Chong VH; Sollano JD; Ahmed F; Menon J; Sung JJ;
    Gastroenterology; 2016 Mar; 150(3):617-625.e3. PubMed ID: 26627608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria.
    Cubiella J; Salve M; Díaz-Ondina M; Vega P; Alves MT; Iglesias F; Sánchez E; Macía P; Blanco I; Bujanda L; Fernández-Seara J
    Colorectal Dis; 2014 Aug; 16(8):O273-82. PubMed ID: 24456168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.